Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women
Status:
Completed
Trial end date:
2019-06-28
Target enrollment:
Participant gender:
Summary
Prospective, open, single-arm trial of dolutegravir-tenofovir and emtricitabine or lamivudine
(DTG-TDF-FTC or 3TC) in antiretroviral (ART) naïve HIV transgender women (TGW).
The primary objective of this pilot study is to determine the retention in care of TGW
treated with DTG-TDF-FTC or 3TC
Secondary objectives:
- To evaluate the efficacy of the antiretroviral regimen at week 48 ;
- To describe the safety and tolerability of this regimen;
- To evaluate adherence across 48 weeks;
- To determine the patient satisfaction with this regimen;
- To identify individual, social and contextual factors associated with adherence and
retention.
Phase:
Phase 4
Details
Lead Sponsor:
Fundación Huésped The Huesped Foundation
Collaborator:
ViiV Healthcare
Treatments:
Dolutegravir Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Lamivudine Tenofovir